Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 4,667 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Signs and Symptoms Clear all
Completed Not applicable Interventional

An mHealth Symptom Management Intervention for Colorectal Cancer Patients (mCOPE)

NCT04763174
View directory record Official record
Conditions
Colorectal Cancer
Interventions
mHealth Coping Skills Training for Symptom Management (mCOPE)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 11, 2026, 1:38 PM EDT
Completed Not applicable Interventional

Acupuncture for Prevention of Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy

NCT05975385
View directory record Official record
Conditions
Cholecystitis, Acute, Cholelithiasis, Nausea, Postoperative, Vomiting, Postoperative, Pain, Postoperative
Interventions
Acupuncture
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 11, 2026, 1:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

NCT05131815
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
Interventions
Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 11, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00082823
View directory record Official record
Conditions
Cancer
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 11, 2026, 1:38 PM EDT
Not yet recruiting Not applicable Interventional

NaviCam Patency Capsule to Verify Gastrointestinal Patency

NCT07649720
View directory record Official record
Conditions
Intestinal Stricture, Crohn Disease, NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy, Abdominal Pain
Interventions
NaviCam Patency Capsule
Device
Lead sponsor
AnX Robotica Corp.
Industry
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Downers Grove, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 11, 2026, 1:38 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Mycobiome Evaluation in Children With Autism & GI Symptoms

NCT03494088
View directory record Official record
Conditions
Autism, Gastrointenstinal Symptoms
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
4 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 11, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT00699166
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DNK333
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Anniston, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2008 · Synced Oct 11, 2026, 1:38 PM EDT
Terminated Not applicable Interventional

Effects of an Amino Acid Mixture on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease

NCT03451253
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Short Bowel Syndrome, Ileostomy - Stoma
Interventions
amino acid mixture beverage, glucose-based sports drink
Other
Lead sponsor
Entrinsic Bioscience Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Nashua, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 11, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

NCT00889486
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
TZP-102, Placebo
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 11, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

NCT00818870
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Omeprazole, Vecam
Drug
Lead sponsor
Vecta Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Oct 11, 2026, 1:38 PM EDT
Terminated Phase 1 Interventional

IGF-1 Therapy in Patients With Cystic Fibrosis

NCT00566241
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
recombinant human IGF-1, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 11, 2026, 1:38 PM EDT
Recruiting Phase 1 Interventional

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT07277413
View directory record Official record
Conditions
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions
IDE892, IDE397
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 11, 2026, 1:38 PM EDT
Not yet recruiting Phase 2 Interventional

Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

NCT07843420
View directory record Official record
Conditions
Chronic Hepatic Pruritus, Cholestatic Liver Disease, Primary Biliary Cholangitis, Cholestasis, Primary Sclerosing Cholangitis
Interventions
Nemolizumab-ilto
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 11, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01271790
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
85
States / cities
Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 11, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional

Tongue-strengthening Exercises in People With ALS.

NCT07295990
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
Interventions
Isometric Lingual Strength Exercises
Procedure
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 11, 2026, 1:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparison of Methods to Detect Polyps During Colonoscopy

NCT01025960
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Standard Inspection Colonoscopy, Dual Inspection Colonoscopy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
768 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 11, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

NCT01542788
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF, RBV, Placebo to match SOF, Placebo to match RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
50
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 11, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effect Of Enamel Matrix Derivatives On Gingival Tissue Thickness

NCT07053969
View directory record Official record
Conditions
Dental Implantation, Missing Teeth, Periodontitis, Adult, Mucositis
Interventions
Enamel Matrix Derivative
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 11, 2026, 1:38 PM EDT
Completed Phase 3 Interventional

Acupuncture For Pancreatic Cancer Pain

NCT00136669
View directory record Official record
Conditions
Pancreatic Neoplasms, Pain
Interventions
Acupuncture
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2006 · Synced Oct 11, 2026, 1:38 PM EDT
Terminated No phase listed Observational

Vestibular Dysfunction as a Cause of Chronic Nausea & Vomiting: A Follow up Survey

NCT01378351
View directory record Official record
Conditions
Dysfunction of Vestibular System, Nausea Persistent, Vomiting
Interventions
Questionnaire survey
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Oct 11, 2026, 1:38 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

NCT01651403
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Tenofovir DF, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
5
States / cities
Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 11, 2026, 1:38 PM EDT
Completed No phase listed Observational

Icodextrin Effects on Glucose Transporter Activation and Mediators of Fibrosis

NCT02133313
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 11, 2026, 1:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Kidney Function in People With Cystic Fibrosis in the Era of HEMT

NCT06595420
View directory record Official record
Conditions
Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Acute Kidney Injury
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
7 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Lebanon, New Hampshire • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 11, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

NCT00381862
View directory record Official record
Conditions
Colorectal Cancer, Nausea and Vomiting
Interventions
aprepitant, dexamethasone, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, palonosetron hydrochloride, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Savannah, Georgia • Hilo, Hawaii • Harvey, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 11, 2026, 1:38 PM EDT